- Home
- KOPN vs CUE Comparison
KOPN vs CUE Comparison
Compare KOPN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOPN | CUE |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.9M | 49.6M |
| IPO Year | 1992 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KOPN | CUE |
|---|---|---|
| Price | $2.30 | $0.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $4.25 | $3.00 |
| AVG Volume (30 Days) | ★ 3.2M | 1.2M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,602,295.00 | $7,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.37 | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.02 | N/A |
| 52 Week Low | $0.71 | $0.23 |
| 52 Week High | $4.16 | $1.75 |
Technical Indicators
Market Signals| Indicator | KOPN | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 40.51 | 33.29 |
| Support Level | $2.32 | $0.23 |
| Resistance Level | $2.44 | $0.33 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 1.79 | 26.85 |
Price Performance
Historical ComparisonAbout KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.